{"organizations": [], "uuid": "6239e9bcae626397642f57f34cbe721382bd43ad", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/27/business-wire-antibe-therapeutics-reports-q3-2018-interim-financial-and-operating-results.html", "country": "US", "domain_rank": 767, "title": "Antibe Therapeutics Reports Q3 2018 Interim Financial and Operating Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T05:45:00.000+02:00", "replies_count": 0, "uuid": "6239e9bcae626397642f57f34cbe721382bd43ad"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/27/business-wire-antibe-therapeutics-reports-q3-2018-interim-financial-and-operating-results.html", "ord_in_thread": 0, "title": "Antibe Therapeutics Reports Q3 2018 Interim Financial and Operating Results", "locations": [], "entities": {"persons": [{"name": "sedar", "sentiment": "none"}, {"name": "antibe", "sentiment": "none"}], "locations": [{"name": "antibe", "sentiment": "none"}], "organizations": [{"name": "antibe therapeutics inc.", "sentiment": "negative"}, {"name": "bnd projects inc.", "sentiment": "none"}, {"name": "antibe therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (\"Antibe\" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, February 27 th for the fiscal quarter ended December 31, 2017. The Company’s unaudited fiscal Q3 2018 condensed interim consolidated financial statements and MD&A are available on SEDAR.\nIn addition, the Company has granted BND Projects Inc. 36,000 options for investor relations services. Each option has an exercise price of $0.29, being the 5-day volume weighted average price of Antibe’s shares, vests quarterly starting on the date of the grant, and will expire February 27, 2021.\nAbout Antibe Therapeutics Inc.\nAntibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com .\nAntibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com .\nForward Looking Information\nThis news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions \"will\", \"anticipate\", \"believe\", \"plan\", \"estimate\", \"expect\", \"intend\", \"propose\" and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its ability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180227006837/en/\nAntibe Therapeutics Inc.\nDan Legault, 416-473 4095\nChief Executive Officer\ndan.legault@antibethera.com\nSource: Antibe Therapeutics Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.antibethera.com&esheet=51765815&newsitemid=20180227006837&lan=en-US&anchor=www.antibethera.com&index=1&md5=94e2594a5cad5f9fe50bc3df0ff038dd", "http://www.businesswire.com/news/home/20180227006837/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.citagenix.com&esheet=51765815&newsitemid=20180227006837&lan=en-US&anchor=www.citagenix.com&index=2&md5=ac4fc12243da420b4dbb65fa033964cb"], "published": "2018-02-28T05:45:00.000+02:00", "crawled": "2018-02-28T06:49:28.007+02:00", "highlightTitle": ""}